期刊文献+

再生障碍性贫血患儿HLA-DRB1*15表达及其与免疫抑制治疗疗效的关系 被引量:8

Expression of HLA-DRB115 Genotype in Children with Acquired Aplastic Anemia and Its Relation to Effect of Immunosuppressive Therapy
下载PDF
导出
摘要 本研究探讨再生障碍性贫血(AA)患儿HLA-DR基因表达情况及其与免疫抑制治疗疗效的关系,评价HLA-DRB1*15基因型检测的临床意义。采用SSP-PCR方法对40例(特发性33例,继发性7例)获得性AA儿童和107名正常对照人群进行HLA-DR位点基因检测,其中32例AA患儿接受了免疫抑制治疗(其中强化免疫抑制治疗24例,单纯CsA治疗8例),比较AA患儿和健康人群HLA-DR基因表达差异,观察AA儿童HLA-DRB1*15表达与免疫抑制治疗疗效、疾病复发的关系。结果显示,特发性AA患儿HLA-DRB1*15(+)率为51.5%(17/33),较正常对照人群(20.6%)显著增高(p<0.01),7例继发性AA患儿均为HLA-DRB1*15(-)。HLA-DRB1*15(+)组AA患儿经免疫抑制治疗后6个月有效率和完全缓解(CR)率分别为93.8%、87.5%,而在HLA-DRB1*15(-)组分别为56.3%和31.3%,两组比较差异均具有极显著意义(p<0.01)。5例复发患儿均为HLA-DRB1*15(+)。结论:AA患儿HLA-DRB1*15基因表达频率较正常人群显著增高,HLA-DRB1*15(+)AA患儿对免疫抑制治疗反应好,疾病完全缓解率高。 This study was purposed to investigate the frequency of HLA-DRB1 * 15 expression in children with aplastic anemia (AA) and its relation to effect of immunosuppressive therapy. HLA-DR genotypes were detected by SSP-PCR in 40 patients with acquired aplastic anemia and 107 normal controls, and the expressions of HLA-DR gene in AA patients and normal controls were compared. 32 out of 40 patients were treated with immunosuppressive therapy, which included antilymphocyte globulin combining with cyclosporine or cyclosporine alone, the relation of HLA-DRB1 * 15 expression to efficacy of immunosuppressive therapy and relapse of AA was explored. The results showed that the mean age of the patients was 9.0 years with a ratio of male to female 1.5 : 1. The frequency of HLA-DRB1 * 15 genotype expression in patients with idiopathic aplastic anemia was 51.5% ( 17/33 ), which was markedly higher than that of healthy controls (20.6% , p 〈0.01 ). All of 7 patients with second acquired aplasitic anemia showed negative expression of HLA -DRB1 * 15. The rates of all responses, including complete remission and partial remission ( CR + PR), and CR to immunosuppressive therapy in 16 patients who beared HLA-DRB1 * 15 were 93. 8% and 87. 5% respectively, which were higher significantly than those of patients without bearing HLA-DRB1 * 15 (56. 3% and 31.3%, p 〈 0.01 ). Relapse occurred in 5 patients who beared HLA-DRB1 * 15 genotype. It is concluded that the frequency of HLA-DRB1 * 15 genotype expression in children with AA is significantly higher than that in normal controls, and the immunosuppressive therapy for patients beared HLA-DRB1 * 15 shows favourable effect with high incidence of complete remission.
出处 《中国实验血液学杂志》 CAS CSCD 2007年第6期1212-1215,共4页 Journal of Experimental Hematology
关键词 再生障碍性贫血 免疫抑制治疗 HLA—DR基因 aplastic anemia immunosuppressive therapy HLA-DR gene
  • 相关文献

参考文献12

  • 1黄永兰,黄绍良,包蓉,张绪超,吴燕峰.再生障碍性贫血儿童TCRVβ亚家族T细胞克隆性增殖及其与HLA-DRB1*15的关系[J].中山大学学报(医学科学版),2006,27(2):165-168. 被引量:11
  • 2中华医学会儿科学分会血液学组.小儿再生障碍性贫血的诊疗建议[J].中华儿科杂志,2001,39(7):422-423. 被引量:74
  • 3Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood, 1976; 48:63 -70
  • 4黄科,黄绍良,方建培,钟凤仪,周敦华,李栋方,岑丹阳.强化免疫抑制治疗儿童再生障碍性贫血疗效分析[J].中山大学学报(医学科学版),2004,25(5):486-488. 被引量:7
  • 5Camitta BM. What is the definition of cure for aplastic anemia? Acta Haematol, 2000; 103:16 - 18
  • 6Usman M, Adil SN, Moatter T, et al. Increased expression of HLA DR2 in acquired aplastic anemia and its impact on response to immunosuppressive therapy. J Pak Med Assoc, 2004 ; 54 : 251 - 254
  • 7Kapustin SI, Popova TI, Lyschov AA, et al. HLA-DR2 frequency increase in severe aplastic anemia patients is mainly attributed to the prevalence of DR15 subtype. Pathol Oncol Res, 1997 ; 3 : 106 - 108
  • 8Zeng W, Maciejewski JP, Chen G, et al. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest, 2001 ; 108 : 765 - 773
  • 9Nakao S, Takami A, Sugimori N, et al. Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1 * 1501 does not predict response to antithymocyte globulin. Br J Haematol, 1996 ; 92 : 155 - 158
  • 10Ihan O, Beksac M, Arslan O, et al. HLA-DR2: a predictive marker in response to cyclosporine therapy in aplastic anemia. Int J Hematol, 1997; 66:291 -295

二级参考文献28

  • 1黄科,黄绍良,方建培,钟凤仪,周敦华,李栋方,岑丹阳.强化免疫抑制治疗儿童再生障碍性贫血疗效分析[J].中山大学学报(医学科学版),2004,25(5):486-488. 被引量:7
  • 2王美娟,何海龙,廖健毅.再生障碍性贫血患儿外周血淋巴细胞表型分析[J].实用儿科临床杂志,2005,20(1):29-30. 被引量:15
  • 3黄永兰,黄绍良,包蓉,张绪超,吴燕峰.再生障碍性贫血儿童TCRVβ亚家族T细胞克隆性增殖及其与HLA-DRB1*15的关系[J].中山大学学报(医学科学版),2006,27(2):165-168. 被引量:11
  • 4Nakao S. Immune mechanism ofaplastic anemia[J]. Int J Hematal,1997,66(2):127-34.
  • 5Rosenfeld S J, Kimball J, Vining D, et al. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia[J]. Blood, 1995,85(1):3058-65.
  • 6Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colonystimulating factor in children with acquired aplastic anemia[J]. Blood, 2000,96(6):2049-54.
  • 7NAKAO S,TAKAMATSU H,YACHIE A,et al.Establishment of a CD4^+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia[J].Exp Hematol,1995,23(5):433-438.
  • 8CAMITTA B M,THOMAS E D,NATHAN D G,et al.A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia[J].Blood,1979,53(3):504-514.
  • 9GORSKI J,YASSAI M,ZHU X,et al.Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectrotyping.Correlation with immune status[J].J Immunol,1994,152(10):5109-5119.
  • 10MELENHORST J J,FIBBE W E,STRUYK L,et al.Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anemia[J].Br J Haematol,1997,96(1):85-91.

共引文献90

同被引文献110

引证文献8

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部